A number of studies have suggested that correcting the loss of tau function may be valuable or more valuable than correcting the toxic gain-of-tau function (including hyperphosphorylation and aggregation), in drug discovery programs for tauopathies (Trojanowski and Lee, 2005). This evidence concerns the gene MAPT and tauopathy.